Apr 29, 2026 04:15PM
Feb 26, 2026 07:30AM
Jan 5, 2026 07:00AM
Jan 5, 2026 07:00AM
Dec 4, 2025 06:35AM
Dec 4, 2025 06:35AM
Nov 6, 2025 07:30AM Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
May 9, 2022 08:30AM
Mar 31, 2022 08:00AM
Mar 16, 2022 09:26AM
Mar 15, 2022 05:51PM
Jan 25, 2022 08:04AM
Jan 25, 2022 08:00AM
Sep 28, 2021 04:03PM Catalyst Biosciences (CBIO) Announces FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
Sep 28, 2021 04:01PM
Aug 5, 2021 08:00AM
Jun 28, 2021 08:08AM
Jun 28, 2021 08:00AM
Mar 4, 2021 08:00AM
Dec 2, 2020 08:03AM
Dec 2, 2020 08:00AM Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors
Aug 18, 2020 04:30PM
Jun 22, 2020 04:05PM
Jun 22, 2020 08:00AM
Jun 19, 2020 11:48AM
Jun 19, 2020 11:45AM
Jun 18, 2020 09:26AM
Jun 18, 2020 09:09AM Catalyst Biosciences (CBIO) Announces Pricing of 4.62M Public Offering of Common Stock at $6.50/sh
Jun 18, 2020 09:00AM
Jun 17, 2020 04:03PM
Jun 17, 2020 04:01PM
Jun 15, 2020 08:05AM
Jun 15, 2020 08:00AM
Jun 15, 2020 07:02AM
Jun 15, 2020 07:00AM Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of Hemophilia Virtual Summit 2020
Jun 12, 2020 08:00AM
Jun 10, 2020 08:10AM
Jun 10, 2020 08:00AM
Jun 8, 2020 08:00AM
May 11, 2020 08:00AM
Apr 28, 2020 08:06AM
Apr 28, 2020 08:00AM Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio
Apr 6, 2020 08:10AM
Apr 6, 2020 08:00AM
Feb 20, 2020 04:05PM
Nov 7, 2019 08:00AM
Aug 1, 2019 08:00AM
Jul 8, 2019 05:55AM
Jul 8, 2019 05:00AM Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhib
May 2, 2019 08:00AM

323,580 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All